In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Research & Development

Vaccines move up the agenda, COVID-19 continues to grow as a new drug development field, and novel modalities boost the overall pharma R&D pipeline.

Biotech’s Cambrian Explosion

An increasing number of sophisticated tools are on offer to address new therapeutic challenges and remaining unmet needs.

COVID-19 R&D: Pharma’s Path Ahead

Global research and development for preventative vaccines and therapeutics to treat COVID-19 have progressed at a rapid pace. Still, key issues remain and to the dampen the effects of virus in 2022, even greater collaboration is needed.

The Next Big Thing In Gene Therapy Might Not Be Gene Therapy

Gene therapy remains attractive when data show new technologies can advance the field, but gene regulation, editing and RNA therapies are grabbing investors’ attention, panelists said at ARM’s Cell and Gene Meeting on the Mesa.

Pneumococcal Vaccines Market Snapshot: Pfizer And Merck Face Off

Pfizer's Prevnar 20 and Merck's Vaxneuvance are launching simultaneously and are expected to help drive vaccines growth for both big pharmas.

Outlook 2022 e-Book

Outlook 2022 cover

Download a PDF copy of the Outlook 2022 collection, including Scrip 100 league tables.

ACCESS NOW
UsernamePublicRestriction

Register